Brief: Menarini Group And Radius Health Submit New Drug Application To The U.S. FDA For Elacestrant

Radius Recycling

22/06/2022 21:32

June 22 (Reuters) - Radius Health Inc  RDUS.O :
    * MENARINI GROUP AND RADIUS HEALTH SUBMIT NEW DRUG
APPLICATION TO
THE U.S. FDA FOR ELACESTRANT
    * RADIUS HEALTH INC - PLAN TO FILE MARKETING AUTHORIZATION
APPLICATION FOR ELACESTRANT IN EU IN 2H 2022
    * RADIUS HEALTH INC - PRIORITY REVIEW REQUESTED; IF
ACCEPTED,
ANTICIPATE AN 8-MONTH FDA REVIEW
    * RADIUS HEALTH INC - MENARINI PLANS TO USE ITS FULLY OWNED
SUBSIDIARY IN U.S., STEMLINE THERAPEUTICS, TO COMMERCIALIZE
ELACESTRANT IF APPROVED BY FDA

Source text for Eikon:  ID:nGNX2762Ml 
Further company coverage:  RDUS.O 

 ((Reuters.Briefs@thomsonreuters.com;))